Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture

Zheng, Shunzhen; Liu, Dejie; Sun, Ping; Guo, Yonglang; Yang, Xu; Gong, Wei; Li, Jun

doi:10.3748/wjg.v20.i43.16275

Cited by 12 publications

(13 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Searching the reference list (snowball procedure) retrieved two additional articles. In total, 67 studies were deemed eligible and therefore included in the systematic review …”

Section: Resultsmentioning

confidence: 99%

“…The mean age of the study population was 55.6 years (SD = 6.64) with most patients being male (77.9%). A large portion of the cohort population consisted of patients from Asia, as 22 studies (33%) were from China, 17 (25%) from Japan, 10 (15%) from Taiwan, 5 (7.5%) from Korea, 2 (3%) from Thailand, and 1 (1.5%) each from Singapore and Malaysia . In contrast, studies about rHCC were less common from Western centers with only 2 reports (3%) from the Netherlands and Italy, and 1 (1.5%) each from Canada, France, United Kingdom, USA, and Nigeria .…”

Section: Resultsmentioning

confidence: 99%

“…Thirty‐five studies provided data on short‐term survival (Table ) . The leading causes of death in the short‐term was demise either from bleeding complications (34.3%) or hepatic failure (30.0%).…”

Section: Resultsmentioning

confidence: 99%

“…Not surprisingly, various therapeutic strategies had differing effects on OS (Table and Supplementary Table S7) . Among all included studies, the estimated cumulative 1‐, 3‐, and 5‐year OS was 46.4%, 28.4%, and 17.6%, respectively, in the patient cohort who were managed with a combination of therapies.…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Management, outcomes, and prognostic factors of ruptured hepatocellular carcinoma: A systematic review

Moris

Chakedis

Sun

et al. 2017

Journal of Surgical Oncology

View full text Add to dashboard Cite

Ruptured hepatocellular (rHCC) is a rare but life-threatening presentation that often requires acute intervention. In this systematic review we identified 67 eligible studies reporting on 4941 patients with rHCC. Here we present the treatment approaches for the management of rHCC both in the acute setting with regards to management of hemorrhage, as well long-term with regards to oncological treatment.

show abstract

“…Searching the reference list (snowball procedure) retrieved two additional articles. In total, 67 studies were deemed eligible and therefore included in the systematic review …”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Management, outcomes, and prognostic factors of ruptured hepatocellular carcinoma: A systematic review

Moris

Chakedis

Sun

et al. 2017

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…Usually, sorafenib was given as 400 mg bid. [8] In our patient population mainly three types of dosing regimen were used. They are 400 mg bd, 600 mg daily, and 200 mg bid with good compliance.…”

Section: Treatmentmentioning

confidence: 99%

Efficacy of sorafenib therapy in patients with advanced hepatocellular carcinoma in Indian population

Abraham¹,

Purushothaman²,

Damien³

et al. 2016

View full text Add to dashboard Cite

Aim: Hepatocellular carcinoma (HCC) is the fourth most common type of cancer and the third leading cause of cancer-related mortality. Sorafenib is an oral multikinase inhibitor that is used for unresectable advanced HCC. It is only approved systemic therapy for advanced HCC. Methods: A retrospective prospective study conducted in a multispeciality hospital with 50 patients who received sorafenib. The primary outcome of the study was to find out the survival rate of patients treated with sorafenib. The secondary outcome of the study was to explore the efficacy and safety of sorafenib in a progression of HCC. Results: The median overall survival in the Indian population was found as 114 days (3.8 months) after sorafenib therapy. The efficacy of the drug sorafenib was assessed by the survival days which were based on the changes in laboratory values such as haematological and clinical biochemistry. The adverse drug reaction documented in this study was vomiting, abdominal pain; fatigue; anorexia; hyperbilirubinemia; diarrhoea; hand-foot syndrome; rash; rectal bleeding; insomnia; constipation; thrombocytopenia and abdominal discomfort. Conclusion: Sorafenib improves the overall survival of the patients with advanced HCC in Indian population up to 3.8 months. It is a safe and effective treatment for patients with advanced HCC in Indian population. The survival of patients was found to be depended on the liver function.

show abstract

Impact of spontaneous tumor rupture on prognosis of patients with T4 hepatocellular carcinoma

Chan

Hung

Pan

et al. 2016

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background and objectivesCompare the outcomes of three groups of patients with T4 hepatocellular carcinoma (HCC): tumor rupture with shock (RS group), tumor rupture without shock (R group), and no tumor rupture (NR group).Materials and MethodsWe retrospectively reviewed 221 patients with T4 HCC from 2010 to 2012. The clinical background and prognosis were analyzed.ResultsOverall in‐hospital mortality rate was 18.1%; overall median survival time was 4 months. The NR group were more likely to have multiple and infiltrative tumors (P < 0.001). Relative to the NR group, the R + RS group had better survival rates at 6 months (49.2% vs. 32.2%), 1 year (35.3% vs. 21.0%), 3 years (22.5% vs. 11.0%), and 5 years (17.7% vs. 5.5%) (P = 0.010). Patients in the RS group had a higher in‐hospital mortality rate, but significantly better long‐term survival than the NR and R group (P < 0.001). Multivariate analysis indicated that Child‐Pugh class B or C, presence of portal venous thrombosis, and absence of shock were significantly associated with poor survival.ConclusionPatients with tumor rupture and shock had worse in‐hospital survival. However, patients without decompensated liver cirrhosis and portal venous thrombosis, and eligible for curative treatment had favorable long‐term outcome. J. Surg. Oncol. 2016;113:789–795. © 2016 The Authors. Journal of Surgical Oncology Published by Wiley Periodicals, Inc.

show abstract

Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture

Abstract: Sorafenib can be used in patients with ruptured HCC as it has interesting activity and is well tolerated; dose adjustment is generally not required. However, a larger prospective study is necessary to determine the efficacy of sorafenib in this group of patients.

Cited by 12 publications

References 30 publications

Management, outcomes, and prognostic factors of ruptured hepatocellular carcinoma: A systematic review

Management, outcomes, and prognostic factors of ruptured hepatocellular carcinoma: A systematic review

Efficacy of sorafenib therapy in patients with advanced hepatocellular carcinoma in Indian population

Impact of spontaneous tumor rupture on prognosis of patients with T4 hepatocellular carcinoma

Contact Info

Product

Resources

About